Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Rectal Neoplasms 13Squamous Cell Carcinoma of Head and Neck 11Esophageal Neoplasms 11Uterine Cervical Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Head and Neck Neoplasms 7Pancreatic Neoplasms 6Oropharyngeal Neoplasms 6Nasopharyngeal Carcinoma 6Carcinoma, Squamous Cell 5Esophageal Squamous Cell Carcinoma 3Carcinoma 3Thymoma 2Stomach Neoplasms 2Neoplasms by Site 2Neoplasms 2NSCLC 2Lymphoma 2Hypopharyngeal Neoplasms 2Glioblastoma 2Colorectal Neoplasms 2Adenocarcinoma Of Esophagus 2Urinary Bladder Neoplasms 1Thrombocytopenia 1Small Cell Lung Carcinoma 1Sinonasal undifferentiated carcinoma 1Sinonasal Squamous Cell Carcinoma 1SCLC, Extensive Stage 1Resectable Esophageal Cancer 1Rectal Malignant Neoplasms 1

Interventions

anlotinib 1Radiotherapy 1Immunotherapy 1Drug Therapy 1Docetaxel 1Cisplatin 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Locally Advanced Non-small Cell Lung Cancer × Chemoradiotherapy × Clear all
NCT05481775 2022-11-21

Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Sun Yat-sen University

Phase 2 Withdrawn
Thoracic

Locally Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡